Federal Circuit affirms ruling on Regeneron inequitable conduct
The US Court of Appeals for the Federal Circuit has affirmed a ruling of a lower court that found a patent owned by Regeneron unenforceable because of the biotech company’s inequitable conduct.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
2 January 2018 The US Court of Appeals for the Federal Circuit has rejected Regeneron’s request for a panel rehearing and rehearing en banc in a case centring on inequitable conduct.
2 January 2018 The US Court of Appeals for the Federal Circuit has rejected Regeneron’s request for a panel rehearing and rehearing en banc in a case centring on inequitable conduct.
2 January 2018 The US Court of Appeals for the Federal Circuit has rejected Regeneron’s request for a panel rehearing and rehearing en banc in a case centring on inequitable conduct.